ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE

L E G N A R O (PD)

N. 458 del 27/09/2019

OGGETTO: Approvazione dello schema di contratto cd. ``Biological Material Transfer Agreement for Research Purposes`` tra l`Istituto Zooprofilattico Sperimentale delle Venezie e l`Universita` di Ghent per il trasferimento di ceppi influenzali a bassa patogenicita`.

Atto sottoscritto digitalmente ai sensi del D.Lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa

ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE

L E G N A R O (PD)

DELIBERAZIONE DEL DIRETTORE GENERALE

OGGETTO: Approvazione dello schema di contratto cd. ``Biological Material Transfer Agreement for Research Purposes`` tra l`Istituto Zooprofilattico Sperimentale delle Venezie e l`Universita` di Ghent per il trasferimento di ceppi influenzali a bassa patogenicita`.

Si sottopone al Direttore generale f.f. la seguente relazione del Responsabile della SCA1 – Risorse Umane, Rapporti Esterni e Gestione Documenti.

Si premette che:

- ai sensi dell’art. 1, comma 6, del D.Lgs. n. 270/1993 e dell’art. 9, comma 2, del D.Lgs. n. 106/2012 “Gli Istituti, in relazione allo svolgimento delle loro competenze, possono stipulare convenzioni o contratti di consulenza per la fornitura di servizi e per l’erogazione di prestazioni ad enti, associazioni, organizzazioni pubbliche e private, sulla base di disposizioni regionali […]”;

- l’Istituto Zooprofilattico Sperimentale delle Venezie, nel quadro dei propri compiti istituzionali – di cui all’art. 3, dell’Accordo sulla gestione dell’IZSVe approvato dalla Regione del Veneto, dalla Regione Autonoma Friuli Venezia Giulia e dalle Province Autonome di Trento e Bolzano, rispettivamente, con Leggi n. 5/2015, n. 9/2015, n. 5/2015 e n. 5/2015 – provvede all’effettuazione di ricerche di base e finalizzate per lo sviluppo delle conoscenze nell’igiene e sanità veterinaria, nella sicurezza alimentare e nutrizione, secondo programmi e anche mediante convenzioni con università e istituti di ricerca italiani e stranieri, nonché su richiesta dello Stato, delle Regioni, delle Province autonome e di enti pubblici e privati;

- l’IZSVe ha ottenuto importanti riconoscimenti a livello sia nazionale che internazionale nell’ambito del monitoraggio delle principali malattie aviarie virali; è, infatti, sede, tra

Atto sottoscritto digitalmente ai sensi del D.Lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa

Pagina 1 di 5

X.X.X.Xx – Deliberazione del DIRETTORE GENERALE

l’altro, del Centro di Referenza Nazionale e del Laboratorio di referenza OIE e FAO per l’influenza aviaria e la malattia di Newcastle e, a partire dal 1° gennaio 2019, a seguito della fuoriuscita della Gran Bretagna dall’Unione Europea e la conseguente dismissione del Centro di Referenza per l’Influenza Aviaria e la Malattia di Newcastle, incardinato in APHA, è stato individuato quale Centro di Riferimento Europeo per l’Influenza Aviaria e per la Malattia di Newcastle – EURL;

- con nota acquisita al prot. IZSVe n. 10380/2019 l’Università di Ghent, con sede in Belgio, ha richiesto all’IZSVe di addivenire alla stipula di un contratto per il trasferimento di determinati ceppi virali a bassa patogenicità da utilizzare a fini di ricerca;

- il Ministero della Salute – Direzione Generale della Sanità Animale e del Farmaco Veterinario, con nota trasmessa via PEC, acquisita al prot. IZSVe n. 10729/2019, ha autorizzato l’invio dei predetti ceppi.

Pertanto, al fine di formalizzare il rapporto, è stato concordato tra le parti il contratto in lingua inglese cd. “Biological Material Transfer Agreement for research purposes”, per la fornitura dei ceppi predetti meglio descritti nell’art. 1 dell’Agreement, documento che si allega al presente provvedimento quale parte integrante e sostanziale (allegato n. 1).

Con ticket intranet n. 133804/2019, la “SCS5 – Ricerca e Innovazione” dell’IZSVe ha richiesto a questa Struttura di procedere con gli adempimenti necessari alla stipula del contratto in parola.

L’IZSVe con il predetto contratto, la cui efficacia decorrerà dalla data di sottoscrizione e fino al completamento delle attività di ricerca da parte della citata Università belga si impegna a fornire il suddetto materiale virologico a titolo gratuito, salvo il costo per le spese di spedizione che saranno sostenute dal destinatario.

Tutto ciò premesso, sulla base degli elementi riportati dal referente dell’istruttoria, si propone al Direttore generale f.f. quanto segue:

1. di approvare lo schema di contratto in lingua inglese, cd. “Biological Material Transfer Agreement for research purposes”, da sottoscrivere tra l’IZSVe, nella persona del Direttore generale f.f. e legale rappresentante pro tempore, Dott.ssa Xxxxxxx Xxxxx e l’Università di Ghent, con sede in Belgio, nella persona del Dr. Wim Van Camp, in qualità di legale rappresentante, documento che si allega al presente provvedimento quale parte integrante e sostanziale (allegato n. 1), per il trasferimento di ceppi virali a bassa patogenicità da utilizzare a fini di ricerca;

2. di procedere, per l’effetto, alla sottoscrizione del contratto di cui al punto che precede, ai sensi degli artt. 15 e 16 del vigente Accordo interregionale sulla gestione dell’Istituto Zooprofilattico Sperimentale delle Venezie;

3. di prendere atto che l’IZSVe con il predetto contratto, efficace a decorrere dalla data di sottoscrizione e fino al completamento delle attività di ricerca da parte della citata Università belga si impegna a fornire a titolo gratuito, salvo il costo per le spese di spedizione a carico del destinatario, materiale virologico da utilizzare a fini di ricerca.

IL DIRETTORE GENERALE F.F.

Atto sottoscritto digitalmente ai sensi del D.Lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa

Pagina 2 di 5

X.X.X.Xx – Deliberazione del DIRETTORE GENERALE

ESAMINATA la proposta di deliberazione del Responsabile della SCA1 – Risorse Umane, Rapporti Esterni e Gestione Documenti che attesta la regolarità della stessa in ordine ai contenuti sostanziali, formali e di legittimità dell’atto, attestazione allegata al presente provvedimento.

VISTA l’attestazione di copertura della spesa, ove prevista, allegata al presente provvedimento.

VISTA la DDG n. 164 del 27 marzo 2018 con la quale la dott.ssa Xxxxxxx Xxxxx è stata nominata Direttore sanitario dell’Istituto.

VISTA la DDG n. 166 del 11 aprile 2019 avente ad oggetto “Applicazione dell’art. 3, comma 6, del D.Lgs. 502/1992 e s.m.i. e dell’art. 16, comma 5, dell’Accordo per la gestione dell’Istituto tra la Regione Veneto, la Regione Autonoma Friuli-Venezia Giulia, la Provincia Autonoma di Bolzano e la Provincia Autonoma di Trento, approvato con atto normativo degli Enti cogerenti. Presa d’atto” con la quale si prende atto che, a decorrere dal 13 aprile 2019, le funzioni di Direttore generale sono svolte dal Direttore sanitario ai sensi delle sopracitate disposizioni.

VISTA la DDG n. 332 del 22 luglio 2016 con la quale il Xxxx. Xxxxx Xxxxxxxx è stato nominato Direttore amministrativo dell’Istituto.

ACQUISITO il parere favorevole del Direttore amministrativo per quanto di competenza, espresso ai sensi dell’art. 15, comma 3, dello Statuto dell’Istituto, adottato con DCA n. 16 del 3 agosto 2015 e approvato con DGRV n. 1320 del 9 ottobre 2015.

VISTO l’art. 15 del D.Lgs. n. 106 del 28 giugno 2012 il quale, al primo comma, dispone che “… Gli organi degli Istituti in carica alla data di entrata in vigore del presente decreto sono prorogati sino all’insediamento dei nuovi organi”.

VISTO l’Accordo per la gestione dell’Istituto Zooprofilattico Sperimentale delle Venezie tra la Regione del Veneto, la Regione Autonoma Friuli Venezia Giulia e le Province Autonome di Trento e Bolzano, approvato dai suddetti Enti, rispettivamente, con leggi n. 5/2015, n. 9/2015, n. 5/2015 e n. 5/2015.

D E L I B E R A

Atto sottoscritto digitalmente ai sensi del D.Lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa

Pagina 3 di 5

X.X.X.Xx – Deliberazione del DIRETTORE GENERALE

Il presente provvedimento non è soggetto al controllo previsto dall’Accordo per la gestione dell’Istituto Zooprofilattico Sperimentale delle Venezie approvato dagli Enti cogerenti con le leggi regionali e provinciali citate nelle premesse.

IL DIRETTORE GENERALE F.F.

Dott.ssa Xxxxxxx Xxxxx

Sul presente atto deliberativo ha espresso parere favorevole Il Direttore amministrativo

xxxx. Xxxxx Xxxxxxxx

Atto sottoscritto digitalmente ai sensi del D.Lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa

Pagina 4 di 5

X.X.X.Xx – Deliberazione del DIRETTORE GENERALE

ATTESTAZIONI ALLEGATE ALLA DELIBERAZIONE DEL DIRETTORE GENERALE

Il Responsabile della Struttura proponente attesta la regolarità della proposta di deliberazione, presentata per l’adozione, in ordine ai contenuti sostanziali, formali e di legittimità dell’atto e che la stessa:

Comporta spesa  su Finanziamento istituzionale 

Finanziamento vincolato 

Altri finanziamenti 

Non comporta spesa 

ATTESTAZIONE DI COPERTURA ECONOMICA DELLA SPESA

Il Responsabile del Budget attesta l’avvenuto controllo sulla disponibilità di budget

Evidenziato infine che il responsabile della Struttura proponente, con la sottoscrizione della proposta di cui al presente atto, dichiara, sotto la propria responsabilità ed ai sensi e agli effetti degli artt. 47 e 76 del dPR 28 dicembre 2000, n. 445, che, in relazione alla presente procedura, non si trova in condizioni di incompatibilità di cui all’art. 35 bis del d.lgs. n. 165/2001, né sussistono conflitti di interesse di cui all’art. 6 bis della legge n. 241/1990 e agli artt. 6, 7 e 14 del dPR n. 62/2013.

Dott.ssa Xxxxx Xxxxxx

Atto sottoscritto digitalmente ai sensi del D.Lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa

Pagina 5 di 5

ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE

Viale dell’Università 10 – 00000 XXXXXXX (XX)

DELIBERAZIONE DEL DIRETTORE GENERALE N. 458 del 27/09/2019‌

OGGETTO: Approvazione dello schema di contratto cd. ``Biological Material Transfer Agreement for Research Purposes`` tra l`Istituto Zooprofilattico Sperimentale delle Venezie e l`Universita` di Ghent per il trasferimento di ceppi influenzali a bassa patogenicita`.

Pubblicata dal 27/09/2019 al 12/10/2019 Atto immediatamente esecutivo

Il Responsabile della Pubblicazione Xxxxx Xxxxxxx

Elenco firmatari

Questo documento è stato firmato da:

Dott.ssa Xxxxx Xxxxxx - Affari Generali, Progetti e Convenzioni, Servizi Istituzionali e Digitalizzazione xxxx. Xxxxx Xxxxxxxx - Direzione Amministrativa

Dott.ssa Xxxxxxx Xxxxx - Direzione Generale Xxxxx Xxxxxxx - - Gestione Atti

BIOLOGICAL MATERIAL TRANSFER AGREEMENT FOR RESEARCH PURPOSES.

Istituto Zooprofilattico Sperimentale delle Venezie, with offices at Xxxxx xxxx’Xxxxxxxxxx 00, 00000 Xxxxxxx (XX), Xxxxx, fiscal code and VAT n. 00206200289, PEC: xxxxxxxxxx@xxxxxxxxx.xxx, represented by represented by Dr. Xxxxxxx Xxxxx, Acting Director General (Direttore Generale), fiscal personal code n. XXXXXX00X00X000X

hereinafter referred to as “IZSVe” or “Provider”

and

The University of Ghent, a public research university organized under the laws of Belgium, having its registered office at Belgium, B-9000 Gent, Xxxx-Xxxxxxxxxxxxxxxxxx 00, company registration number 0248.015.142, , represented by Wim Van Camp, general manager UGent TechTransfer, acting by delegation pursuant to the Board of Governors' decision, who entrusts the execution of the present agreement to prof. dr. Kristien Van Reeth, Department of Virology, parasitology and immunology, hereinafter referred to as the “ University” or “Recipient”:

and severally as “Party” and jointly as “ Parties”

This Agreement sets out the understanding of the Parties with respect to the provision of certain biological material to the Recipient, which wishes to use the material for non-commercial evaluation purposes only subject to the terms and conditions of this Agreement.

WHEREAS:‌

• IZSVe is a public veterinary Institute which conducts prevention, control and research activities in three main areas: animal health and welfare, food safety, and environmental protection;

• The Recipient is engaged in experimental studies with different influenza viruses in pigs and other mammalian influenza virus hosts and requests to receive certain Material available at IZSVe for research and testing purposes;

• IZSVe agrees to transfer to Recipient the following biological material;

NOW, THEREFORE,

in consideration of the covenants and obligations hereinafter set forth, the Parties hereto, individually and by their respective agents and representatives, hereby agree as follows:

ART. 1. DEFINITIONS

The above mentioned words have the following meanings in this Agreement:

“Effective date”: the date as of which the Agreement enters into force.

“Commercial Purposes”: the sale of products or services, lease, license, or other transfer of the Material or Modifications for any commercial purpose or for the direct benefit of any for- profit entity, including use of the Material or Modifications by any organization, including Recipient, to perform research for third parties who obtain rights in research results, to screen compounds, to produce or manufacture products for general sale, or to conduct any research activities that result in any sale, lease, license, or transfer of the Material or Modifications to a for-profit entity.‌

“Confidential Information”: Information of any nature protected or not by an intellectual property right (data, documents, methods, know-how, etc.) whatever their subject, transmission

Pag. 1 a 9

mode, origin, communicated within the frame of this Agreement. The Material is Confidential Information. Confidential information not include information that:

i. is already known by the Party to which it is disclosed;

ii. is or becomes part of the public domain without breach of this Agreement;

iii. is obtained from third parties that have no obligation to keep confidential to the parties to this Agreement;

iv. is independently developed by the receiving party or its parent corporation or their respective subsidiaries and/or affiliates without the aid, application or use of the Confidential Information (and such independent development can be properly demonstrated by the receiving party); or,

v. is required by law, regulation, rule, act or order of any governmental authority or agency to be disclosed by the receiving party, provided, however, that such receiving party (A) gives the disclosing party sufficient advance written notice to permit it to seek a protective order or other similar order with respect to such Confidential Information and (B) thereafter discloses only the minimum information required to be disclosed in order to comply, whether or not a protective order or other similar order is obtained by such disclosing party.

“Original Material”: the Material to be delivered from IZSVe to the Recipient under the term of this Agreement is as below specified.

Microorganis m or other type of biological material (e.g. serum)	Isolate material (ID)	Year of isolation	Source of isolation	Substrate of isolation	Comment s	Amount
Influenza A virus	A/turkey/Ital y/13VIR- 1864/2013	2013	Turkey			2 ml
Influenza A virus	A/chicken/Ita ly/1670/2015	2015	Chicken			2 ml
Influenza A virus	A/turkey/Ital y/4776- 48/2015	2015	Turkey			2 ml
Influenza A virus	A/turkey/Ital y/8036/2012	2012	Turkey			2 ml
Influenza A virus	A/chicken/Ita ly/3582- 51/10	2010	Chicken			2 ml

“Material”: Original Material, Progeny and Unmodified Derivatives, but does not include Modifications or other substances created by the Recipient through the use of the Material. “Progeny”: an unmodified descendant from the Material, such as virus from virus, cell from cell, or organism from organism.‌

“Unmodified Derivatives”: substances created by the Recipient which constitute an unmodified functional subunit or product expressed by the Original Material (for example subclones of unmodified cell lines, purified or fractionated subsets of the Original Material, proteins expressed by DNA/RNA supplied by the Provider, or monoclonal antibodies secreted by a hybridoma cell line).

“Modifications”: substances created by the Recipient which contain or incorporate the Material.

Pag. 2 a 9

“Patent Rights”: any patents, patent applications, trade secrets or other proprietary rights of the Provider having claims relating to the Original Material, including any altered forms of the Material made by the Provider, and any substitutions, divisions, continuations, continuations- in-part, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates or the like, or provisional applications of any such patents and patent applications, or foreign equivalents thereof.

“Provider's Scientist”: the employees of IZSVe.

“Recipient’s scientist”: Prof. Kristien Van Reeth, who is an employee of the Recipient. “Research activities”: (described in Annex 1) description of the research study planned with the Material.‌

ART. 2. MATERIAL TRANSFER

IZSVe shall supply the Recipient the Original Material within thirty (30) days after the execution of this Agreement by both Parties and received by IZSVe.

The Recipient will contact IZSVe Dr. Xxxxxxxx Xxxxx to agree on the date(s) of shipment. Subject to the terms and conditions herein, the Provider grants to the Recipient a royalty-free, non exclusive license to use the Material solely in performance of the Research activities described in Annex 1 – Description of activities. The Recipient agrees that the Material:‌

a) will not be used for Commercial Purposes; any commercial use of the Material is strictly forbidden. The Recipient undertakes not to sell, disclose, transfer, give or distribute the Material to any third party.

b) will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects without the Provider's prior written consent;

c) will be used only at the Recipient organization and only in the Researcher's laboratories under the direction of the Researcher or others working under his or her direct supervision.

d) will not be further transferred without the Provider's prior written consent.‌

The Recipient will refer any request for the Material from anyone other than those persons working under the Researcher's direct supervision to the Provider's Scientist.

Upon request, the Recipient will provide to IZSVe with a summary of the Research Activities obtained with the Material.

The Recipient will use the Material and Modifications in compliance with all laws and governmental regulations and guidelines applicable to the Material and Modifications.

The Recipient shall ensure that the Recipient's employees, students and agents using the Material and Modifications agree to be bound by the terms of this Agreement.

ART. 3. FEE AND PAYMENT

The Material for the Research activities is provided for free. Shipping costs will be charged on the Recipient.

ART. 4. USE OF THE MATERIAL AND INTELLECTUAL PROPERTY

The Material is owned to the Provider who maintains the ownership of the Material, including any Material contained or incorporated in Modifications.

The Material will be used by the Recipient solely and strictly in connection with performing the Research activities at Recipient’s institutional facilities and under the direction of Recipient’s Scientist only.

Pag. 3 a 9

No rights are provided to Recipient under any patent applications, trade secrets or other proprietary rights of IZSVe. In particular, no rights are provided to use the Material or Modifications for profit-making or commercial purposes, or provision of a commercial service based upon the Material or Modifications. The Material shall not be incorporated into any service or product for sale or used for the commercial provision.

If Recipient desires to use the Material or Modifications for such profit-making or commercial purposes, Recipient agrees that it must first negotiate a license or other appropriate agreement with IZSVe and third parties as may be required, and it is further understood by Recipient that IZSVe shall have no obligation to enter into such a license or agreement.

The Recipient may distribute substances created by the Recipient through the use of the Original Material only if those substances are not Progeny, Unmodified Derivatives, or Modifications with prior written notice to the Provider.

Except as provided in this Agreement, no express or implied licenses or other rights are provided to the Recipient under the Patent Rights. In particular, no express or implied licenses or other rights are provided to use the Material, Modifications, or any related patents of the Provider for Commercial Purposes.

Otherwise any results as well as any know-how, discoveries, inventions and other intellectual property generated by the Recipient through the use of the Material permitted by this Agreement, will be owned by the Recipient.

The Recipient shall destroy the Material and Modifications after completion of Research purpose.

ART. 5. LIABILITY

By requesting the Material and signing this Agreement, the Recipient accepts responsibility for the proper handling and testing of the Material in accordance with generally accepted international scientific standards, including any disposition and guidelines regarding biosecurity, biosafety, health and scientific research. The Recipient guarantees that suitable handling and containment conditions are available and will be applied in the Recipient’s laboratory.

The Recipient represents that within its laboratories:

- the access to the Material and to Modifications will be restricted to personnel capable and qualified to safely handle those substances, using appropriate containment;

- the Recipient shall use the utmost precaution to minimise any risk of harm to persons and property and to safeguard them from theft or misuse.

The Recipient assumes all liability for any and all third party damages and claims arising out of or relating to this Agreement, including the receipt, use, handling, storage, conservation of the Material and Modifications.

The Recipient agrees to indemnify, defend and hold harmless IZSVe and its employees from and against any third party claims, losses, costs, expenses and damages, including reasonable attorneys' fees which may incur, suffer or be required to pay resulting from or arising in connection with the use, handling or storage of Material or Modifications by the Recipient or the Recipient’s personnel, or the breach of any obligation of the Recipient hereunder.

ART. 6. WARRANTY

Pag. 4 a 9

The Recipient acknowledges that the Material are supplied to the Recipient with no information on their use, warranties, express or implied, including but not limited to any warranty of fitness for a particular purpose.

However IZSVe represents and warrants to the Recipient that its execution will not result in a breach of any obligation to any third party or infringe or otherwise violate any third party’s rights. There are no express or implied warranties that the Material and/or Modifications will not pose a safety or health risk.

If the Material is not available for use or not delivered in sufficient amounts, the Recipient shall send a written notification to IZSVe within ten (10) days after the receipt of the Material (or in case non-delivery of Material, within ten (10) days of the agreed date of shipment). In these cases, IZSVe shall replace the Material only. This warranty is valid if the Recipient ensures that the Material has been stored or processed as indicated in the documents that will accompany it. Each Party warrants and represents that it has the right to enter into this Agreement.‌

The parties ensure that they shall respect human rights.

ART. 7. INTELLECTUAL PROPERTY RIGHTS

IZSVe is the owner and has all the rights on the Material, Progeny and Unmodified Derivatives. The transfer does not grant or imply the ownership of the Material, or any intellectual and industrial property rights to the Recipient.

ART. 8. TERM AND TERMINATION

This Agreement is effective when signed by both parties and terminates on completion of the Recipient’s Research activities using the Material.

Before the Material’s shipping to the Recipient, the Agreement may be terminated on thirty

(30) days written notice by either party to the other. This Agreement may be also terminated immediately by the Provider if the Recipient has not cured a breach of this Agreement within seven (7) days of being notified of such breach. Either party may terminate this Agreement with immediate effect by giving notice to the other party if the other party is involved in a serious violation of human rights.

On termination of this Agreement, Recipient will discontinue the use of the Material and will, upon direction of IZSVe return or destroy any remaining Material, Modifications and Confidential Information. The clauses 4-7 shall survive termination of this Agreement.

ART. 9. MISCELLANEOUS

Protection of Personal Data

The parties commit themselves to respect the European Regulation EU 2016/679 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (GDPR) as well as the national applicable laws.

The parties may share personal data of individuals involved in the collaboration such as: name, business telephone, address, and email (“Business Contact Information”). Each party may store and otherwise process such Business Contact Information. The parties agree that Business Contact Information will only be processed for administrative purposes to the limited extent as required for the performance of this Agreement.

If the processing of other than Business Contact Information is necessary for the performance of this Agreement, the parties commit themselves to agree and enter into an amendment to this agreement, which shall be attached to this Agreement to constitute the entire Agreement between the parties in order to reflect each party’s rights and obligations in this respect..

Pag. 5 a 9

Confidential information: The Recipient shall not give, sell, share, release, convey, or otherwise distribute the Material and/or any accompanying Confidential Information to any third party without the prior written permission of IZSVe. The Recipient acknowledges that IZSVe may withhold its consent for any reason it deems necessary and is not obliged to give the reason thereof.

Confidential Information will be safeguarded and not disclosed to any third parties by the receiving party.

Notwithstanding the afore mentioned, the receiving party will have no obligation hereunder to refrain from disclosing or using the information for which it can reasonably prove that:

a) the information is available to the public at the time of its disclosure;

b) the information has become part of the public domain or publicly known or available by publication or otherwise, not due to any unauthorised act or omission on the part of the receiving party;

c) the information has been disclosed to the receiving party by third parties as a matter of right;

d) the information was at the time of disclosure already known to the receiving party on a non-confidential basis prior to its disclosure by the disclosing party;

e) the information is subsequently developed independently by or on behalf of the receiving party, without use of the information.

In case points a) – e) are applied, IZSVe must always be informed beforehand so that compliance to the Agreement may be checked.

The Recipient also undertakes to retain in confidence and not disclose to any third party the Material. The Recipient may disclose the Provider’s Confidential Information to the Recipient’s parent corporations, affiliates and subsidiaries only if such parent corporations, affiliates and subsidiaries agree to be bound by confidentiality and non-use provisions at least as protective of the Provider’s rights as those contained in this Agreement.‌

In the event that the Recipient is requested or required by law or legal process to disclose any of the Confidential Information, the Recipient shall provide IZSVe with prompt written notice before making any disclosure. In addition, Confidential Information may be disclosed to the extent required in the course of inspections or inquiries by EU Federal or State regulatory agencies to whose jurisdiction IZSVe and/or the Recipient is/are subject to and that has/have the legal right to inspect documents containing the Confidential Information. The Recipient shall promptly advise IZSVe upon such disclosure and vice versa.

Publication: The Recipient is free to release scientific publications concerning the outcomes of the scientific research carried out with the Material. Every publication referred to the Material and Modification shall acknowledge the source of the Material, giving the due reference to IZSVe.

Entire Agreement: This Agreement constitutes the entire understanding of the Parties with respect to the matters contained herein, superseding all prior oral or written understandings or communications between the Parties relating to the present Agreement. This Agreement may be amended, modified, superseded or canceled, only by a written instrument executed by each Party’s duly authorized representatives.

Force Majeure: IZSVe shall not be liable for failure of or delay in supplying Strains set forth in this Agreement, and shall not be deemed in breach of its obligations, if such failure, delay or incorrect performance is due to natural disasters or any causes beyond its reasonable control including, without limitation, any act of God, any civil commotion or strike. In the event of such force majeure, IZSVe thereby shall promptly notify the other Party in writing. If the force

Pag. 6 a 9

majeure lasts more than 90 days, the Party shall have the right to terminate the Agreement; the notice of termination shall be made according to the present article 8.

Assigment: This Agreement and the rights, obligations and duties set forth herein may not be assigned, transferred, delegated or sub-contracted by the Recipient without the prior written consent of the IZSVe.

Governing Law: This Agreement shall be governed interpreted and construed in accordance with the laws of Italy. Any disputes, controversies or differences which may arise between the Parties out of or in connection with this agreement, its interpretation or performance, shall be submitted to the exclusive jurisdiction of the Court of Padua, Italy, without regard to the conflicts of law provisions.

Notices: All notices and communications related to this Agreement shall be made by registered or certified letter, return receipt requested, telecopied or electronic transmission confirmed in writing by registered mail and shall be addressed as follows (or to other address as may hereafter be designed by written notice):

If to IZSVe: Att. Xxxxxxxx Xxxxx – Project Investigator Istituto Zooprofilattico Sperimentale delle Venezie Viale dell’Università 10 ‌‌

00000 - Xxxxxxx (XX) - XXXXX

Fax 049/0000000; e-mail xxxxxx@xxxxxxxxxx.xx

Xxxxxxxxx Xxxxxx – Secretariat

Istituto Zooprofilattico Sperimentale delle Venezie Viale dell’Università 10 ‌‌

00000 - Xxxxxxx (XX) - XXXXX

Fax 049/0000000; email xxxxxxx@xxxxxxxxxx.xx

If to the Recipient:


	Ghent University
Dept.	Technology Transfer
Address	p/a Xxxx-Xxxxxxxxxxxxxxxxxx 00 0000 Xxxx Xxxxxxx
Tel	0000 0 000 00 00
E-mail	xxxxxxxxxx@xxxxx.xx xxxx.xxxxxxx@xxxxx.xx